Dr Reddy's Laboratories was bludgeoned on Indian bourses after the firm said that it had received FDA warning letters at three manufacturing sites, including an oncology plant, in India.
Dr Reddy's Laboratories was bludgeoned on Indian bourses after the firm said that it had received FDA warning letters at three manufacturing sites, including an oncology plant, in India.
The announcement, coming days ahead of India's Diwali festival, ruffled investors, who believe that the development could potentially put at...
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.
Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.
Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.
Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.
The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.
The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.
Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.
